Australia's Chimeric Therapeutics climbs on WuXi AppTec unit partnership
12/04/2022 02:21
** Shares of biotech firm Chimeric Therapeutics CHM.AX
rise as much as 10.7% to A$0.155, their best intraday session
since Feb 1
** Says it has entered a manufacturing partnership with WuXi
Advanced Therapies, a unit of WuXi AppTec 603259.SS for its
CAR T cell programmes, a type of cancer therapy urn:newsml:reuters.com:*:nASXjMhx3
** Chimeric to transfer some manufacturing and analytical
testing technologies to the WuXi unit, for development,
manufacturing and testing of the technology
** Stock hits highest level since March 25
** As of last close, CHM down 44.1% this year
(Reporting by Harshita Swaminathan)
((Harshita.Swaminathan@thomsonreuters.com))